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Abstract 
BACKGROUND: Patients undergoing heart surgery involving cardiopulmonary bypass (CPB) experience global 
myocardial ischemia with subsequent reperfusion which, despite cardioplegic protection, may result in different 
degrees of transient ventricular dysfunction. Levosimendan is a “calcium sensitisers”, it improves myocardial 
contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption and without 
impairing relaxation and diastolic function. 
AIM: To evaluate the adding effect of a calcium sensitiser (levosimendan) compared to the conventional inotropic 
and vasoactive agent used in the patient with poor left ventricular function undergoing cardiac surgery on different 
measured hemodynamic variables and the effect on the outcome. 
METHODS: It is prospective observational studies were patients were divided into 2 groups of 30 patients each. 
The first Group received conventional inotropic and vasoactive treatment at different doses, while the other group 
received levosimendan additionally at a loading dose of 6-12mic/kg according to mean arterial pressure over 0.5 
hr followed by 24 hrs infusion at 0.05 to 0.2 mic/kg/min. Hemodynamic data were collected at the end and 30 
minutes after CPB, after that at 6, 12, 24, and 36 hours post CPB. Mean arterial pressure (MAP), central venous 
pressure (CVP), heart rate (HR), mixed venous saturation (Svo2), and base deficit (BD) were measured. 
RESULTS: Levosimendan had significantly improved postoperative hemodynamic values as in the mixed venous 
pressure at different times postoperative (p < 0.05), also the base deficit at different times postoperative (p < 
0.05), while there was a significant reduction in systemic vascular resistance as decreased mean arterial pressure 
in levosimendan group compared to conventional group at 6hrs postoperative mean 77.50 ± 10.81 vs 83.73 ± 
10.81 with (p = 0.029), and at 12 hrs postoperative mean 77.37 ± 10.10vs 84.23 ± 13.81 with (p = 0.032), and 
there was no significant difference in heart rate at different times postoperative between both groups (p > 0.05), 
while there was no significant effect on mortality between both groups (p = 0.781). 
CONCLUSION: Levosimendan had improved hemodynamic parameters significantly with no effect on mortality 
compared to conventional inotropic agents in a patient with poor left ventricular function undergoing cardiac 
surgery. 
 
 
 
 
 
Introduction 
 
Patients undergoing heart surgery involving 
cardiopulmonary bypass (CPB) experience global 
myocardial ischemia with subsequent reperfusion 
which, despite cardioplegic protection, may result in 
different degrees of transient ventricular dysfunction, 
also known as myocardial stunning in the immediate 
postoperative period [1], [2].
 
If severe enough, this 
dysfunction can cause postoperative low cardiac 
output syndrome, a complication with an estimated 
prevalence of about10% and a mortality of 17% [3].
 
Pharmacological support, in the form of 
vasodilator and inotropic therapy, as well as 
mechanical support, such as intra-aortic balloon 
counterpulsation and ventricular assist devices, is 
often necessary to restore adequate tissue perfusion 
in the immediate postoperative period [2].
 
Perioperatively, the most frequently used inotropes 
are beta-adrenergic and phosphodiesterase III 
inhibitors [4], [5], [6].
  
Levosimendan is a recently introduced 
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indicator, it belongs to a novel group of agents called 
calcium sensitisers, which increase the sensitivity of 
contractile proteins to calcium. The use of this agent 
in the treatment of decompensated heart failure is 
based on its dual mechanism of action. It improves 
myocardial contractility by sensitising troponin C to 
calcium without increasing myocardial oxygen 
consumption [7] and without impairing relaxation and 
diastolic function [8].
 
Also, it causes the opening of 
ATP-dependent potassium channels on smooth 
muscle fibres, which induces systemic, pulmonary and 
coronary vasodilatation and may offer cardioprotective 
effects during myocardial ischaemia [9], [10], [11].
 
Furthermore, growing evidence from in vitro 
and in vivo studies indicates that, unlike other 
inotropes, levosimendan does not affect or even 
improves diastolic function in failing myocardium [12], 
[13], [14], [15].
 
We aimed to evaluate the adding effect of a 
calcium sensitiser (levosimendan) compared to the 
conventional inotropic and vasoactive agent used in 
the patient with poor left ventricular function 
undergoing cardiac surgery on different measured 
hemodynamic variables and the effect on the 
outcome. 
 
 
Patients and Method 
 
Our study was a prospective observational 
study, conducted from the period of May 2016 to May 
2017, in which patients admitted to the intensive care 
units following cardiac surgery in different cardiac 
surgery centres (Cardiothoracic Department, Cairo 
University and other cardiothoracic centres, Cairo, 
Egypt).  
A total of 60 patients were enrolled in our 
study and were subsequently divided into two groups 
30 patients each, group received conventional 
inotropic and vasoactive treatment, while the other 
group received levosimendan additionally at loading 
dose 6-12 mic/kg according to mean arterial pressure 
over 0.5 hr followed by 24 hrs infusion at 0.05 to 0.2 
mic/kg/min. Hemodynamic data were collected at the 
end and 30 minutes after CPB, after that at 6, 12, 24 
and 36 hours post CPB. Mean arterial pressure 
(MAP), central venous pressure (CVP), heart rate 
(HR), mixed venous saturation (Svo2) and base deficit 
(BD) were measured. 
 
Inclusion criteria 
All patients with poor preoperative left 
ventricle function ejection fraction < 35% undergoing 
cardiac surgery for valvular, coronary bypass or aortic 
aneurysm repair. 
Exclusion criteria 
Patients with congenital heart disease. 
Patients with allergy to levosimendan. 
All patients enrolled in our study were 
subjected to: 
- Full history and clinical examination. 
- Preoperative logistic EUROSCOREII 
evaluation. 
- Laboratory investigation including: 
- Complete blood count. 
- Renal and liver function tests. 
- Coagulation profile. 
- Pre and postoperative echocardiography. 
- Chest x-ray. 
- ECG. 
 
Statistical analysis 
Data were collected, revised, coded and 
entered to the statistical package for social science 
(IBM SPSS) version 20. Qualitative data were 
presented as number and percentages, while 
quantitative data were presented as mean, standard 
deviations and ranges. The comparison between two 
groups with qualitative data was made by using Chi-
square test, the comparison between two independent 
groups with quantitative data and parametric 
distribution was made by using Independent t-test, 
while the Mann Whitney test is done for two 
independent samples with nonparametric distribution 
and the comparison between more than two groups 
with quantitative data and parametric distribution was 
done by using One Way ANOVA test. The p-value 
was considered significant if < 0.05. 
 
 
Results 
 
Our study enrolled a total of 60 patients: 46 
males (77%), 14 females (23%), who were admitted to 
ICU following cardiac surgery with preoperative 
echocardiography revealing impaired cardiac 
functions EF < 35%. 
Demographic data were presented in Table 1. 
There was no significant statistical difference between 
both groups (p > 0.05) regarding age, gender, 
preoperative ejection fraction, while there was a 
significant statistical higher incidence of BMI, 
diabetes, hypertension in the levosimendan compared 
to conventional group (p = 0.001, 0.002, 0.005 
respectively).  
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Table 1: Study group demographic data 
Demographic data 
 Conventional group Levosimendan group P 
value No. = 30 No. = 30 
Age 
Mean ± SD 55.20 ± 8.59 59.67 ± 9.84 0-066 
Range 34 – 72 30 – 74 
Gender 
Male 20 (66.7%) 26 (86.7%) 0-067 
Female 10 (33.3%) 4 (13.3%) 
Body mass index 
Mean ± SD 
Range 
30.93 ± 2.56 
24 – 36 
33.50 ± 3.05 0-001 
29 – 39 
Diabetic 
No 
Yes 
19 (63.3%) 
11 (36.7%) 
7 (23.3%) 0.002 
23 (76.7%) 
Hypertensive 
 
No 
Yes 
28 (93.3%) 
2 (6.7%) 
19 (63.3%) 
11 (36.7%) 
0-005 
Preoperative ejection 
Fraction 
Mean ± SD 
Range 
33.20 ± 3.35 
20 – 36 
31.80 ± 4.44 
20 – 37 
0.173 
 
 
Heart Rate  
There was no statistically significant 
difference regarding heart rate at any time 
postoperative between the two groups (p > 0.05) as 
presented in Table 2. 
Table (2): Comparison of postoperative measured heart rate 
between both groups 
Heart rate 
Conventional group Levosimendan group P-value 
No. = 30 No. = 30 
Immediate 
postoperative 
Mean ± SD 102.13 ± 14.00 101.57 ± 20.08 0.900 
Range 77 – 132 65 – 160 
0.5hr 
postoperative 
Mean ± SD 101.90 ± 13.17 101.90 ± 19.71 1.000 
Range 71 – 124 76 – 170 
6hrs 
postoperative 
Mean ± SD 101.73 ± 12.67 99.17 ± 18.94 0.540 
Range 71 – 125 62 – 146 
12hrs 
postoperative 
Mean ± SD 102.13 ± 15.14 101.50 ± 18.99 0.887 
Range 70 – 139 73 – 163 
24hrs 
postoperative 
Mean ± SD 102.90 ± 15.83 106.33 ± 20.72 0.474 
Range 75 – 142 63 – 150 
36hrs 
postoperative 
Mean ± SD 97.33 ± 18.96 107.37 ± 23.67 0.075 
Range 60 – 140 54 – 170 
 
 
Mean arterial blood pressure  
Regarding mean arterial pressure, there was 
a statistically significant difference between both 
groups at 6hrs postoperative wherein the conventional 
group mean arterial pressure was higher 83.73 ± 
10.81mmHg compared to the levosimendan group 
mean arterial pressure was 77.50 ± 10.81 mmHg (p = 
0.029).  
 
Figure 1: Mean arterial pressure between both groups (PO) 
postoperative; (#) significant P-value 
 
Also, there was a statistically significant 
difference between both groups at 12 hrs 
postoperatively wherein the conventional group mean 
arterial pressure was higher 84.23 ± 13.81 mmHg 
compared to the levosimendan group mean arterial 
pressure was 77.37 ± 10.10 mmHg (p = 0.032). While 
there was no statistically significant difference at 
immediate, 0.5 hr, 24hrsand at 36hrs postoperatively 
(p > 0.05) as shown in Figure 1. 
 
Central venous pressure (CVP) 
 Regarding central venous pressure, there 
was statistically significant lower CVP at 6hrs 
postoperative in the conventional group with median 
6.00 (3.00 – 9.00) cm H2O compared to the 
levosimendan group median was10.00 (5.00 – 12.00) 
cmH2O (p = 0.004). Also, there was statistically 
significant lower CVP at 12hrs postoperative in the 
conventional group with median 7.50 (4.00 – 9.00) 
cmH2O compared to the levosimendan group median 
10.00 (9.00 – 13.00) cmH2O (p = 0.006). 
There was no statistically significant 
difference at immediate, 0.5 hr, 24 hrs and 36 hrs 
postoperatively (P > 0.05) as shown in Figure 2. 
 
Figure 2: Central venous pressure between both groups (PO); 
postoperative (#) significant P-value 
 
Base deficit 
There was a highly statistically significant 
higher base deficit in the conventional group 
compared to the levosimendan group at immediate, 
0.5 hr, 6 hrs, 24 hrs and 36 hrs postoperatively (p = 
0.001, 0.001, 0.009, 0.021 and 0.001) respectively. 
While there was no statistically significant difference in 
the base deficit between both groups at 12 hrs 
postoperatively (p = 0.104) as shown in Figure 3. 
 
Figure 3: Base deficit between both groups (PO) postoperative; (#) 
significant P-value 
 
Mixed venous oxygen saturation 
There was a highly statistically significant 
higher mixed venous oxygen saturation in the 
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levosimendan group compared to the conventional 
group at immediate, 0.5 hr, 6 hrs, 12 hrs, 24 hrs and 
36hrs postoperatively (p = 0.013, 0.015, 0.032, 0.024, 
0.005 and 0.011) respectively as shown in Figure 4. 
 
Figure 4: Mixed venous pressure between both groups 
 
Outcome 
Postoperative ejection fraction was 
significantly higher in the levosimendan group than 
the conventional group (p = 0.002), length of hospital 
stay was significantly lower in the levosimendan group 
than in conventional group (p = 0.028). Also, there 
was a statistically significant higher logistic 
EUROSCOREII in the levosimendan group than in the 
conventional group (p = 0.046) as presented in Table 
3. 
Table 3: Outcomes in the conventional and levosimendan 
group 
Outcomes 
 Conventional 
group 
Levosimendan 
group 
P 
value 
 No. = 30 No. = 30 
Postoperative ejection 
fraction 
Mean ± SD 
Range 
33.73 ± 2.96 
25 – 39 
36.90 ± 4.53 
25 – 44 
0.002 
Mechanical ventilation 
duration 
in hours 
Mean ± SD 
Range 
51.43 ± 66.29 
6 – 288 
43.27 ± 36.48 
6 – 120 
0.557 
Length of ICU stay in 
days 
Mean ± SD 
Range 
4.03 ±2.71 
2 – 12 
3.27 ± 1.68 
2 – 8 
0.193 
Length of hospital stay 
in days 
Mean ± SD 
Range 
15.43 ± 9.70 
5 – 46 
10.87 ± 5.41 
5 – 29 
0.028 
Logistic EUROSCOREII Median (IQR) 
Range 
1.88 (1.20 – 3.57) 
0.76 – 21.06 
3.19 (1.76 – 6.70) 
0.68 – 21.72 
0.046 
 
 There was no statistically significant 
difference between both groups regarding mortality 
with lower mortality in the levosimendan group 9 
patients (30%) did not survive compared to 
conventional group were10 patients (33.3%) did not 
survive (p = 0.781) as presented in Table 4. 
Table 4: Mortality in the two study groups 
Mortality 
Conventional group Levosimendan group P-value 
No. = 30 No. = 30 
Survival 
Non survival 
20 (66.7%) 21 (70.0%) 0.781 
10 (33.3%) 9 (30.0%) 
 
 
 
Discussion 
 
In our study using of levosimendan achieved 
statistically significant improvement in left ventricular 
function (EF%) postoperatively determined by 
echocardiography compared to conventional group 
(36.90 ± 4.53 VS 33.73 ± 2.96), (p = 0.002). 
 Supporting our results Husedzinovic et al., 
[16]
 
in a double-blind, randomised trial evaluating the 
effect of levosimendan as a new strategy during off-
pump coronary artery bypass grafting enrolling 24 
patients received either placebo or levosimendan at a 
dose of 12 mic/kg as an infusion for 15 min before 
CABG. At 10 min and 60 min post-infusion, the 
cardiac index and the LVEF were significantly higher 
with levosimendan than with placebo (P = 0.018 
each). The stroke volume index was significantly 
higher for levosimendan at 10 min (P = 0.018), but not 
at 60 min (P = 0.063). 
In concordance to our study, Barisin S et al., 
[17]
 
in his study levosimendan in off-pump coronary 
artery bypass: a Four-time masked, controlled study 
enrolling 31 patients: 10 patients received a high 
dose,10 patients received a low dose, and 11 patients 
received a placebo. 
Two dose schedules: low dose(12 mic/kg), 
high dose (24 mic/kg) over 10min; treatment was 
given 20min before start of surgery result in significant 
increases in cardiac output and LVEF occurred after 
high-dose (P = 0.001; P = 0.006) and low-dose 
levosimendan (P = 0.001; P = 0.002). Both 
levosimendan doses produced significant increased 
stroke volume and decreased systemic vascular 
resistance. 
In our study, the heart rate showed no 
significant statistical difference at all times 
postoperative between both groups (p > 0.05). 
This went side by side with Stefan G. DeHert 
et al., [18]
 
who conducted a study enrolling 30 patients 
evaluating the effects of levosimendan in cardiac 
surgery patients with poor left ventricular function had 
found that there was no statistically difference in the 
heart rate at all times postoperatively between both 
groups (p > 0.05). 
Also, Polychronis Malliotakis et al., [19]
 
who 
conducted a study enrolling12 patients evaluating the 
hemodynamic effects of levosimendan for low cardiac 
output after cardiac surgery had determined that there 
were no significant changes in heart rate 
postoperatively (p > 0.05).
 
In contrast, Ravikumar Gandham et al., [20]
 
who conducted a study enrolling 60 patients 
evaluating a comparison of hemodynamic effects of 
levosimendan and dobutamine in patients undergoing 
mitral valve repair/replacement for severe mitral 
stenosis had found that there was a significant 
difference in heart rate being higher in the 
conventional group at mostly all times postoperatively 
(p < 0.05) this variance may be due to that he was 
mainly comparing dobutamine with levosimendan. 
In our recent study, the mean arterial 
pressure was statistically significant at 6 and 12 hrs 
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postoperatively (p = 0.029 and 0.032 respectively) 
being higher in the conventional group than the 
levosimendan group. 
This was concordance to Julian Alvarez et al., 
[21]
 
who conducted a study enrolling 50 patient 
evaluating the hemodynamic effects of levosimendan 
compared with dobutamine in patients with low 
cardiac output after cardiac surgery had found that 
there was a significant mean arterial pressure 
difference between both groups at 6, 12, 24 and 48 
hrs postoperatively (p < 0.05) being higher in the 
conventional group. 
Polychronis Malliotakis et al., [19]
 
showed 
significance mean arterial pressure difference 
between both groups at 6 and 24 hrs postoperatively 
(p < 0.05) being higher in the conventional group. 
Ravikumar Gandham et al., [20]
 
had found 
that significance means arterial pressure difference 
between both groups at immediate, 6 and 12 hrs 
postoperatively (p < 0.05) being higher in the 
conventional group. 
Those agreements may be conducted to 
systemic and pulmonary vasodilator effect of 
levosimendan, leading to a reduction in blood 
pressure. 
In our study, evaluating central venous 
pressure at 6 and 12 hrs postoperatively were 
statistically significant (p = 0.004 and 0.006 
respectively) between both groups were lower in the 
conventional group. 
In concordance to our results other studies 
like Julian Alvarez et al., [21]
 
had found that significant 
difference in central venous pressure at 6, 12, 24 and 
48 hrs postoperatively between both groups with (p < 
0.05). 
Polychronis Malliotakis et al.
 
determined that 
there was a significant difference in central venous 
pressure at 6, 12 and 24 hrs postoperatively from 
baseline levosimendan infusion (p < 0.05). 
Ravikumar Gandham et al., [20]
 
found that 
there was a significant difference in central venous 
pressure at immediate, 6 and 12 hrs postoperatively 
from baseline levosimendan infusion with (p < 0.05). 
They all found that there was a significant 
reduction in central venous pressure in levosimendan 
group as a result of a reduction in systemic and 
pulmonary vascular resistance this variation from our 
study may be due to there was no fixed postoperative 
IV fluid protocol among our patients. 
 
In the current work, we used base deficit and 
mixed venous saturation being an indicator for 
adequate cardiac output and tissue perfusion they 
were strongly significant at almost all times 
postoperatively more base deficit in the conventional 
group than levosimendan group and higher mixed 
venous saturation in the levosimendan group than 
conventional group (p < 0.05).
 
In concordance with other studies Julian 
Alvarez et al., [21]
 
showed that significant difference in 
mixed venous oxygen saturation at 6, 12, 24 and 48 
hrs postoperatively between both groups with (p < 
0.05). 
Polychronis Malliotakis et al., [19]
 
determined 
that there was a significant difference in mixed venous 
oxygen saturation at 6, 12 and 24 hrs postoperatively 
from baseline levosimendan infusion (p < 0.05). 
Also, E. Al shawaf et al., [22]
 
who conducted a 
study enrolling 30 cardiac surgery patients comparing 
levosimendan Vs milrinone in type2 diabetic patient 
with low LVEF undergoing elective coronary artery 
surgery found that there were significantly higher 
cardiac index and mixed venous oxygen saturation 
with levosimendan (p < 0.05), significantly lower 
pulmonary capillary wedge pressure, systemic 
vascular resistance and oxygen extraction ratios. 
In our study, there was no statistically 
significant difference in mortality between the 
conventional and levosimendan groups (10 patients 
Vs 9 patients) with (p = 0.781). 
Our results went hand by hand with Stefan G. 
DeHert et al., [18],
 
who showed a non-significant 
effect on mortality (p = 0.224). 
Also, Rajendrah Mehta et al., [23]
 
in the mega 
trial levo.cts enrolled 880 patients evaluating the effect 
of levosimendan in patients with left ventricular 
systolic dysfunction undergoing cardiac surgery on 
cardiopulmonary bypass had found that levosimendan 
did not affect the primary outcome (mortality) (p = 
0.45). Other studies like Julian Alvarez et al., [21],
 
Polychronis Malliotakis et al., [19], and Ravikumar 
Gandham et al., [20]
 
they were focusing mainly on the 
hemodynamic effect of levosimendan. 
Limitation: The present study has the 
following limitations: 
1. The small number of patients was a 
certainly serious drawback. 
2. Presence of several confounding factors 
(e.g. mode and parameters of mechanical ventilation, 
amount of fluids or blood products infused during the 
observation period). 
3. Lack of invasive cardiac function monitoring 
(cardiac index, stroke volume index, systemic and 
pulmonary vascular resistance) that might have 
affected our results cannot be ruled out.  
4. The infusion of the drug beyond 36hours, 
particularly in the subgroup with low cardiac output 
syndrome, will not be addressed in the study. As we 
seek to evaluate the efficacy of levosimendan on the 
short and intermediate-term outcomes in patients 
undergoing high-risk cardiac surgery on CPB and will 
be unable to provide insights into the long-term 
efficacy of the drug. 
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In conclusion: 
- Significant improvement in postoperative 
ejection fraction in the group receiving levosimendan 
(p = 0.002) and significant decrease in-hospital stay (p 
= 0.028). 
- Significant improvement in hemodynamic 
parameters base deficit (p < 0.05) at almost all times 
postoperative, mixed venous Saturation (p < 0.05) at 
almost all times postoperative with no effect on heart 
rate (p > 0.05), with a mild reduction in mean arterial 
pressure due to inodilator effect of levosimendan. 
- Levosimendan had no significant effect on 
mortality compared to the conventional group (p = 
0.781). 
- We recommend an increasing number of the 
study population, use fixed IV fluid protocol and more 
invasive cardiac function monitoring. 
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